Skip to main content
Articles
- New Scientific Committee members announced
- Catalysing new thinking on the development of cancer
- OPTIMISTICC: New connection drives poor outcomes in bowel cancer
- Metabolic fingerprinting reveals link between dietary fat restriction and therapy response
- Nature Reviews Drug Discovery: addressing cancer’s grand challenges
- The power of discovery: 7 teams leading the way
- The Challenges: Professor Sir David Lane shares his thoughts on the macromolecules challenge
- AACR Cancer Discovery: Cancer Grand Challenges to fund broad, pressing research
- AACR Cancer Discovery In Focus: embarking on a new era of discovery
- The Challenges: Professor Crystal Mackall on the solid tumours in children challenge
- The Challenges: Professor René Bernards on the senescence challenge
- STORMing Cancer's Professor Don Ingber receives prestigious Wilbur Cross Medal
- The Challenges: Professor Karen Vousden on the normal phenotypes challenge
- Multidisciplinary collaboration driving new discoveries: uncovering the role of SLC7A5 in KRAS-driven colorectal cancer
- Pre-application webinar: everything you need to know about applying
- The Challenges: Professor Nic Jones on dormancy
- The Challenges: Ed Harlow shares his thoughts on the inflammation challenge
- News from the IMAXT team: Expansion Sequencing technology
- The Challenges: Professor Charlie Swanton discusses the cachexia challenge
- “We wanted to do everything we could to support them”: Nick and Annette Razey give £1m to back Cancer Grand Challenges team
- The Challenges: Professor Charlie Swanton discusses the extrachromosomal DNA challenge
- Professor Barbara Rimer on aspiring to create an inclusive world #IWD2021
- Michele Cleary on celebrating women in science #IWD2021
- Challenging the status quo and collaborating across disciplines in the IMAXT team #IWD2021
- The value of good mentorship: Amy Schade and Karen Cichowski celebrate #IWD2021
- Kimmie Ng and Candace Henley celebrate the value of the patient advocacy voice in cancer research #IWD2021
- Could the size of fat cells around DCIS breast lesions predict risk of future invasive cancer?
- The Challenges: Professor David Hunter shares his thoughts on e-cigarettes
- The microbiome: a biomarker for colorectal cancer?
- In conversation with Owen Sansom and Helen Matthews, SPECIFICANCER
- AACR Meet the Experts Session
- Inside Project Theia, the world’s first virtual reality cancer research lab – and a call for volunteers
- 7 Questions with... Jelle Wesseling, PRECISION
- Caitlin Brennan discusses the microbiome and aspirin's potential in personalised prevention
- Survival of the fittest: revealing the early stages of APC-driven colorectal cancer
- Announcing the shortlist for the Cancer Grand Challenges awards
- Questions with...Johanna Joyce, IMAXT
- Questions with...Mike Stratton, Mutographs
- A COSMIC catalogue of cancer data, with Mutographs' Ellie Dunstone
- IMAXT’s Nic Walton: uniting across disciplines to share learnings in data science
- Cindy Sears: the power of preclinical models and learnings from global health
- 7 Questions with... John Marioni, IMAXT
- Discover: a year of scientific creativity
- New findings, old ideas: reviving a decades old view on the causes of cancer
- Unravelling the drivers of immune evasion in head and neck cancer
- Escape from the immune system
- New thinking on the process of ageing
- A step closer to distinguishing harmless from invasive breast lesions
- Hidden treasure: do the clues to preventing and detecting colorectal cancer lie in the microbiome?
- Matrix remodelling in the transformation from inflammation to malignancy
- Uncharted territory: metabolic tumour maps reveal new therapeutic avenues
- Genes in space: the future of biology is spatial
- The rules (not the exceptions) of cancer tissue specificity
- “We can all be agents of change” - learnings from our first Future Leaders Conference
- Unravelling the mystery of oesophageal cancer incidence, by Mutographs’ Sarah Moody
- Unexpected findings from the Mutographs team: huge global variation in oesophageal cancer incidence is not due to a unique pattern of DNA damage
- Why virtual reality is the future